Transthyretin amyloid (ATTR) cardiomyopathy is a progressive disease caused by the infiltration of ATTR fibrils in the myocardium. Although it is a rare disease, ATTR cardiomyopathy is an important cause of heart failure with preserved ejection fraction, and its incidence is increasing due to improved diagnostic imaging tools. There has been a breakthrough in the field of transthyretin amyloidosis, which opens a new therapeutic door for the patients. In this review, an overview of tafamidis therapy in ATTR cardiomyopathy with recent results from clinical trials will be discussed.
Citations
Citations to this article as recorded by
A Comprehensive Review on Chemistry and Biology of Tafamidis in
Transthyretin Amyloidosis Monali B. Patil, Piyush Ghode, Prashant Joshi Mini-Reviews in Medicinal Chemistry.2024; 24(6): 571. CrossRef
Multimodal Imaging and Biomarkers in Cardiac Amyloidosis Mi-Hyang Jung, Suyon Chang, Eun Ji Han, Jong-Chan Youn Diagnostics.2022; 12(3): 627. CrossRef